<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01606137</url>
  </required_header>
  <id_info>
    <org_study_id>GWEXT0102</org_study_id>
    <nct_id>NCT01606137</nct_id>
  </id_info>
  <brief_title>A Study of the Long-term Safety of Sativex Use</brief_title>
  <official_title>A Long-term, Open Label, Safety and Tolerability Study of Cannabis Based Medicine Extract in Patients Who Have Participated in a GW Clinical Study Using Cannabis Based Medicine.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GW Pharmaceuticals Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GW Pharmaceuticals Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects who had previously received GW-1000-02 in a GW study who opted to continue using it
      in the long-term were monitored for ongoing tolerability and evidence of clinical benefit.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects who had previously participated in a placebo controlled GW clinical study were
      screened and if eligible began dosing with GW-1000-02. Subjects were reviewed for
      tolerability and evidence of clinical benefit at weeks two and four and then every eight
      weeks. Subjects self-titrated to symptom resolution or maximum tolerated/allowable dose of
      130 mg THC and 120 mg CBD.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">December 2004</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse Events as a Measure of Subject Safety.</measure>
    <time_frame>Up to 1051 days</time_frame>
    <description>Following data entry, all adverse events were medically encoded using the Medical Dictionary for Regulatory Activities (MedDRA) 6.0. All subjects who experienced an adverse event during the treatment period is presented.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Parent Study Baseline in Spasticity 0-10 Numerical Rating Scale Score After 52 Weeks of Treatment.</measure>
    <time_frame>0 - 52 weeks</time_frame>
    <description>Subjects were asked to rate the severity of their primary symptom each week in the diary using an 11-point Numerical Rating Scale, where zero = &quot;best possible&quot; and 10 = &quot;worst possible&quot;. A negative value indicates an improvement in score from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Parent Study Baseline in Central Neuropathic Pain 0-10 Numerical Rating Scale Score at 52 Weeks of Treatment.</measure>
    <time_frame>0 - 52 weeks.</time_frame>
    <description>Subjects were asked to rate the severity of their primary symptom each week in the diary using an 11-point Numerical Rating Scale, where zero = &quot;best possible&quot; and 10 = &quot;worst possible&quot;. A negative value indicates an improvement in score from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Parent Study Baseline in Neuropathic Pain 0-10 Numerical Rating Scale Score at 52 Weeks of Treatment in Multiple Sclerosis Subjects.</measure>
    <time_frame>0 - 52 weeks.</time_frame>
    <description>Subjects were asked to rate the severity of their primary symptom each week in the diary using an 11-point Numerical Rating Scale, where zero = &quot;best possible&quot; and 10 = &quot;worst possible&quot;. A negative value indicates an improvement in score from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Parent Study Baseline in Pain 0-10 Numerical Rating Scale Score at 52 Weeks of Treatment.</measure>
    <time_frame>0 - 52 weeks.</time_frame>
    <description>Subjects were asked to rate the severity of their primary symptom each week in the diary using an 11-point Numerical Rating Scale, where zero = &quot;best possible&quot; and 10 = &quot;worst possible&quot;. A negative value indicates an improvement in score from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Benefit at the Last Study Visit in Those Experiencing Neuropathic Pain Due to Multiple Sclerosis.</measure>
    <time_frame>Up to 1051 days</time_frame>
    <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the subject, and the number of subjects who perceived a benefit from treatment is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment of Benefit at the Last Study Visit in Those Experiencing Neuropathic Pain Due to Multiple Sclerosis.</measure>
    <time_frame>Up to 1051 days</time_frame>
    <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the investigator, and the number of subjects that investigators considered to have experienced a benefit from the treatment is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Benefit at the Last Study Visit in Those Experiencing Central Neuropathic Pain.</measure>
    <time_frame>Up to 1051 days</time_frame>
    <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the subject, and the number of subjects who perceived a benefit from treatment is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment of Benefit at the Last Study Visit in Those Experiencing Central Neuropathic Pain.</measure>
    <time_frame>Up to 1051days</time_frame>
    <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the investigator, and the number of subjects that investigators considered to have experienced a benefit from the treatment is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Benefit at the Last Study Visit in Those Experiencing Pain.</measure>
    <time_frame>Up to 1051</time_frame>
    <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the subject, and the number of subjects who perceived a benefit from treatment is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment of Benefit at the Last Study Visit in Those Experiencing Pain.</measure>
    <time_frame>Up to 1051 days</time_frame>
    <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the investigator, and the number of subjects that investigators considered to have experienced a benefit from the treatment is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject Assessment of Benefit at the Last Study Visit in All Multiple Sclerosis Subjects.</measure>
    <time_frame>Up to 1051 days</time_frame>
    <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the subject, and the number of subjects who perceived a benefit from treatment is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Assessment of Benefit at the Last Study Visit in All Multiple Sclerosis Subjects.</measure>
    <time_frame>Up to 1051 days.</time_frame>
    <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the investigator, and the number of subjects that investigators considered to have experienced a benefit from the treatment is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment at the Last Study Visit in Subjects With Neuropathic Pain Due to Multiple Sclerosis.</measure>
    <time_frame>Up to 1051 days</time_frame>
    <description>Investigators rated the global severity of the subject's underlying primary condition, e.g. their MS or spinal cord injury, since the previous visit using a five point scale of &quot;much worse&quot;, &quot;worse&quot;, &quot;no change&quot;, &quot;better&quot;, &quot;much better&quot;. The number of subjects rated by the investigator as &quot;better&quot; or &quot;much better&quot; at the last study visit is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment at the Last Study Visit in Subjects With Central Neuropathic Pain.</measure>
    <time_frame>Up to 1051 days.</time_frame>
    <description>Investigators rated the global severity of the subject's underlying primary condition, e.g. their MS or spinal cord injury, since the previous visit using a five point scale of &quot;much worse&quot;, &quot;worse&quot;, &quot;no change&quot;, &quot;better&quot;, &quot;much better&quot;. The number of subjects rated by the investigator as &quot;better&quot; or &quot;much better&quot; at the last study visit is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment at the Last Study Visit in Subjects With Pain.</measure>
    <time_frame>Up to 1051 days.</time_frame>
    <description>Investigators rated the global severity of the subject's underlying primary condition, e.g. their MS or spinal cord injury, since the previous visit using a five point scale of &quot;much worse&quot;, &quot;worse&quot;, &quot;no change&quot;, &quot;better&quot;, &quot;much better&quot;. The number of subjects rated by the investigator as &quot;better&quot; or &quot;much better&quot; at the last study visit is presented.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator Global Assessment at the Last Study Visit in Subjects With Multiple Sclerosis.</measure>
    <time_frame>Up to 1051 days.</time_frame>
    <description>Investigators rated the global severity of the subject's underlying primary condition, e.g. their MS or spinal cord injury, since the previous visit using a five point scale of &quot;much worse&quot;, &quot;worse&quot;, &quot;no change&quot;, &quot;better&quot;, &quot;much better&quot;. The number of subjects rated by the investigator as &quot;better&quot; or &quot;much better&quot; at the last study visit is presented.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">507</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Spasticity</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>GW-1000-02</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Active treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GW-1000-02</intervention_name>
    <description>Contained delta-9-tetrahydrocannabinol (THC) (27 mg/ml) and cannabidiol (CBD) (25 mg/ml) as extract of Cannabis sativa L., with peppermint oil, 0.05% (v/v), in ethanol:propylene glycol (50:50) excipient. Each 100 Î¼l actuation of the pump action spray delivered 2.7 mg THC and 2.5 mg CBD. A maximum daily exposure of 130 mg THC was specified by the UK regulatory authority authorisation.</description>
    <arm_group_label>GW-1000-02</arm_group_label>
    <other_name>Sativex</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Willing and able to give informed consent.

          -  Male or female aged 18 years or above.

          -  Diagnosed with a condition categorised as one of the following: multiple sclerosis,
             spinal cord conditions, peripheral nerve injury or central nervous system damage
             associated with vascular, traumatic, infective, genetic or metabolic disease and whose
             symptom(s) were not wholly relieved by currently available therapy, prior to the
             previous study of GW-1000-02 or placebo.

          -  Had participated in a GW clinical study using GW-1000-02 within the previous month.

          -  Had shown tolerability to the study medication during the previous GW study.

          -  Was expected, by the investigator, to gain clinical benefit from receiving long-term
             GW-1000-02.

          -  Were willing, if female and of child bearing potential or male subjects with a partner
             of child bearing potential, to ensure that effective contraception was used during the
             study and for three months thereafter.

          -  Had not used cannabinoids (cannabis, Marinol or Nabilone) for at least seven days
             before Visit 1 (the exception being GW-1000-02 given as study medication) and were
             willing to abstain from any use of cannabis during the study.

          -  Recent (within seven days) haematology and blood chemistry that was normal or
             considered clinically acceptable in view of the subjects underlying condition.

          -  Able (in the investigators opinion) and willing to comply with all study requirements.

          -  Willing for the Home Office to be notified of his or her participation in the study.

          -  Willing to allow his or her general practitioner and consultant, if appropriate, to be
             notified of participation in the study.

        Exclusion Criteria:

          -  History of serious psychiatric illness, including schizophrenia, other psychotic
             illness or severe personality disorder other than depression associated with the
             underlying condition.

          -  Known or strongly suspected of alcohol or substance abuse or considered by the
             investigator to have been at risk of alcohol or substance abuse.

          -  Severe cardiovascular disorder, such as ischaemic heart disease, arrhythmias (other
             than well controlled atrial fibrillation), poorly controlled hypertension or severe
             heart failure.

          -  History of epilepsy or convulsions.

          -  Significant renal or hepatic impairment.

          -  Terminally ill.

          -  Any other significant disease or disorder which, in the opinion of the investigator,
             may have either put the subject at risk because of participation in the study, or may
             have influenced the result of the study, or the subject's ability to participate in
             the study.

          -  Female subjects who were pregnant, lactating or planning pregnancy during the course
             of the study.

          -  Regular levodopa (Sinemet, Sinemet Plus, Levodopa, L-dopa, Madopar, Benserazide)
             therapy within seven days of study entry.

          -  Known or suspected hypersensitivity to cannabinoids or any of the excipients of the
             study medication.

          -  Known or suspected adverse reaction to cannabinoids.

          -  Donation of blood during the study.

          -  Previous participation in this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Serpell, ChB FRCA</last_name>
    <role>Principal Investigator</role>
    <affiliation>Gartnavel General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Gartnavel General Hospital</name>
      <address>
        <city>Glasgow</city>
        <zip>G12 0YN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <results_reference>
    <citation>Serpell MG, Notcutt W, Collin C. Sativex long-term use: an open-label trial in patients with spasticity due to multiple sclerosis. J Neurol. 2013 Jan;260(1):285-95. doi: 10.1007/s00415-012-6634-z. Epub 2012 Aug 10.</citation>
    <PMID>22878432</PMID>
  </results_reference>
  <verification_date>June 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 21, 2012</study_first_submitted>
  <study_first_submitted_qc>May 23, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 25, 2012</study_first_posted>
  <results_first_submitted>July 19, 2012</results_first_submitted>
  <results_first_submitted_qc>July 19, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 23, 2012</results_first_posted>
  <last_update_submitted>June 13, 2013</last_update_submitted>
  <last_update_submitted_qc>June 13, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Sclerosis</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>GW-1000-02</title>
          <description>Each actuation of oromucosal spray delivers 2.7mg delta-9-tetrahydrocannabinol (THC) and 2.5mg cannabidiol (CBD). The maximum permitted dose of was eight actuations in any three hour period, and 48 actuations in any 24 hour period (THC 130 mg : CBD 120 mg).</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="507"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="262"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="85"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="74"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="56"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient non-compliance</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Decreased/no pain</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Issues with driving</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>multiple sclerosis less stable</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Increased bilirubin</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Spray causes nausea</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Not enough improvement</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Wanted to try another treatment</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient leaving country</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to tolerate study med. taste</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient moving</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unable to collect consistent data</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GW-1000-02</title>
          <description>Active treatment</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="507"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="458"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50" spread="12.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="288"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="219"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United Kingdom</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="507"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Adverse Events as a Measure of Subject Safety.</title>
        <description>Following data entry, all adverse events were medically encoded using the Medical Dictionary for Regulatory Activities (MedDRA) 6.0. All subjects who experienced an adverse event during the treatment period is presented.</description>
        <time_frame>Up to 1051 days</time_frame>
        <population>All subjects who took part in the extension study were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events as a Measure of Subject Safety.</title>
          <description>Following data entry, all adverse events were medically encoded using the Medical Dictionary for Regulatory Activities (MedDRA) 6.0. All subjects who experienced an adverse event during the treatment period is presented.</description>
          <population>All subjects who took part in the extension study were included in the analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="507"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Parent Study Baseline in Spasticity 0-10 Numerical Rating Scale Score After 52 Weeks of Treatment.</title>
        <description>Subjects were asked to rate the severity of their primary symptom each week in the diary using an 11-point Numerical Rating Scale, where zero = &quot;best possible&quot; and 10 = &quot;worst possible&quot;. A negative value indicates an improvement in score from baseline.</description>
        <time_frame>0 - 52 weeks</time_frame>
        <population>All subjects who entered the study from a parent randomised controlled trial (RCT) investigating the efficacy of GW-1000-02 in the treatment of spasticity associated with multiple sclerosis, and who received at least one actuation of study medication were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Parent Study Baseline in Spasticity 0-10 Numerical Rating Scale Score After 52 Weeks of Treatment.</title>
          <description>Subjects were asked to rate the severity of their primary symptom each week in the diary using an 11-point Numerical Rating Scale, where zero = &quot;best possible&quot; and 10 = &quot;worst possible&quot;. A negative value indicates an improvement in score from baseline.</description>
          <population>All subjects who entered the study from a parent randomised controlled trial (RCT) investigating the efficacy of GW-1000-02 in the treatment of spasticity associated with multiple sclerosis, and who received at least one actuation of study medication were included in the efficacy analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="61"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" spread="2.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Parent Study Baseline in Central Neuropathic Pain 0-10 Numerical Rating Scale Score at 52 Weeks of Treatment.</title>
        <description>Subjects were asked to rate the severity of their primary symptom each week in the diary using an 11-point Numerical Rating Scale, where zero = &quot;best possible&quot; and 10 = &quot;worst possible&quot;. A negative value indicates an improvement in score from baseline.</description>
        <time_frame>0 - 52 weeks.</time_frame>
        <population>All subjects who entered the study from a central neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Parent Study Baseline in Central Neuropathic Pain 0-10 Numerical Rating Scale Score at 52 Weeks of Treatment.</title>
          <description>Subjects were asked to rate the severity of their primary symptom each week in the diary using an 11-point Numerical Rating Scale, where zero = &quot;best possible&quot; and 10 = &quot;worst possible&quot;. A negative value indicates an improvement in score from baseline.</description>
          <population>All subjects who entered the study from a central neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="62"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.96" spread="2.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Parent Study Baseline in Neuropathic Pain 0-10 Numerical Rating Scale Score at 52 Weeks of Treatment in Multiple Sclerosis Subjects.</title>
        <description>Subjects were asked to rate the severity of their primary symptom each week in the diary using an 11-point Numerical Rating Scale, where zero = &quot;best possible&quot; and 10 = &quot;worst possible&quot;. A negative value indicates an improvement in score from baseline.</description>
        <time_frame>0 - 52 weeks.</time_frame>
        <population>All subjects who entered the study from a neuropathic pain in multiple sclerosis parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Parent Study Baseline in Neuropathic Pain 0-10 Numerical Rating Scale Score at 52 Weeks of Treatment in Multiple Sclerosis Subjects.</title>
          <description>Subjects were asked to rate the severity of their primary symptom each week in the diary using an 11-point Numerical Rating Scale, where zero = &quot;best possible&quot; and 10 = &quot;worst possible&quot;. A negative value indicates an improvement in score from baseline.</description>
          <population>All subjects who entered the study from a neuropathic pain in multiple sclerosis parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="63"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.11" spread="1.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Parent Study Baseline in Pain 0-10 Numerical Rating Scale Score at 52 Weeks of Treatment.</title>
        <description>Subjects were asked to rate the severity of their primary symptom each week in the diary using an 11-point Numerical Rating Scale, where zero = &quot;best possible&quot; and 10 = &quot;worst possible&quot;. A negative value indicates an improvement in score from baseline.</description>
        <time_frame>0 - 52 weeks.</time_frame>
        <population>All subjects who entered the study from a pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Parent Study Baseline in Pain 0-10 Numerical Rating Scale Score at 52 Weeks of Treatment.</title>
          <description>Subjects were asked to rate the severity of their primary symptom each week in the diary using an 11-point Numerical Rating Scale, where zero = &quot;best possible&quot; and 10 = &quot;worst possible&quot;. A negative value indicates an improvement in score from baseline.</description>
          <population>All subjects who entered the study from a pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="131"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.57" spread="2.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Assessment of Benefit at the Last Study Visit in Those Experiencing Neuropathic Pain Due to Multiple Sclerosis.</title>
        <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the subject, and the number of subjects who perceived a benefit from treatment is presented.</description>
        <time_frame>Up to 1051 days</time_frame>
        <population>All multiple sclerosis subjects who entered the study from a neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Assessment of Benefit at the Last Study Visit in Those Experiencing Neuropathic Pain Due to Multiple Sclerosis.</title>
          <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the subject, and the number of subjects who perceived a benefit from treatment is presented.</description>
          <population>All multiple sclerosis subjects who entered the study from a neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Assessment of Benefit at the Last Study Visit in Those Experiencing Neuropathic Pain Due to Multiple Sclerosis.</title>
        <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the investigator, and the number of subjects that investigators considered to have experienced a benefit from the treatment is presented.</description>
        <time_frame>Up to 1051 days</time_frame>
        <population>All multiple sclerosis subjects who entered the study from a neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Assessment of Benefit at the Last Study Visit in Those Experiencing Neuropathic Pain Due to Multiple Sclerosis.</title>
          <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the investigator, and the number of subjects that investigators considered to have experienced a benefit from the treatment is presented.</description>
          <population>All multiple sclerosis subjects who entered the study from a neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Assessment of Benefit at the Last Study Visit in Those Experiencing Central Neuropathic Pain.</title>
        <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the subject, and the number of subjects who perceived a benefit from treatment is presented.</description>
        <time_frame>Up to 1051 days</time_frame>
        <population>All subjects who entered the study from a neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Assessment of Benefit at the Last Study Visit in Those Experiencing Central Neuropathic Pain.</title>
          <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the subject, and the number of subjects who perceived a benefit from treatment is presented.</description>
          <population>All subjects who entered the study from a neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Assessment of Benefit at the Last Study Visit in Those Experiencing Central Neuropathic Pain.</title>
        <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the investigator, and the number of subjects that investigators considered to have experienced a benefit from the treatment is presented.</description>
        <time_frame>Up to 1051days</time_frame>
        <population>All subjects who entered the study from a neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Assessment of Benefit at the Last Study Visit in Those Experiencing Central Neuropathic Pain.</title>
          <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the investigator, and the number of subjects that investigators considered to have experienced a benefit from the treatment is presented.</description>
          <population>All subjects who entered the study from a neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="168"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Assessment of Benefit at the Last Study Visit in Those Experiencing Pain.</title>
        <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the subject, and the number of subjects who perceived a benefit from treatment is presented.</description>
        <time_frame>Up to 1051</time_frame>
        <population>All subjects who entered the study from a pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Assessment of Benefit at the Last Study Visit in Those Experiencing Pain.</title>
          <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the subject, and the number of subjects who perceived a benefit from treatment is presented.</description>
          <population>All subjects who entered the study from a pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="193"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Assessment of Benefit at the Last Study Visit in Those Experiencing Pain.</title>
        <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the investigator, and the number of subjects that investigators considered to have experienced a benefit from the treatment is presented.</description>
        <time_frame>Up to 1051 days</time_frame>
        <population>All subjects who entered the study from a pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Assessment of Benefit at the Last Study Visit in Those Experiencing Pain.</title>
          <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the investigator, and the number of subjects that investigators considered to have experienced a benefit from the treatment is presented.</description>
          <population>All subjects who entered the study from a pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="314"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="190"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Subject Assessment of Benefit at the Last Study Visit in All Multiple Sclerosis Subjects.</title>
        <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the subject, and the number of subjects who perceived a benefit from treatment is presented.</description>
        <time_frame>Up to 1051 days</time_frame>
        <population>All subjects who entered the study from a multiple sclerosis parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
          </group>
        </group_list>
        <measure>
          <title>Subject Assessment of Benefit at the Last Study Visit in All Multiple Sclerosis Subjects.</title>
          <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the subject, and the number of subjects who perceived a benefit from treatment is presented.</description>
          <population>All subjects who entered the study from a multiple sclerosis parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="286"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Assessment of Benefit at the Last Study Visit in All Multiple Sclerosis Subjects.</title>
        <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the investigator, and the number of subjects that investigators considered to have experienced a benefit from the treatment is presented.</description>
        <time_frame>Up to 1051 days.</time_frame>
        <population>All subjects who entered the study from a multiple sclerosis parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Assessment of Benefit at the Last Study Visit in All Multiple Sclerosis Subjects.</title>
          <description>Assessment of benefit achieved at study completion/withdrawal was evaluated by the investigator, and the number of subjects that investigators considered to have experienced a benefit from the treatment is presented.</description>
          <population>All subjects who entered the study from a multiple sclerosis parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="287"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="200"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Global Assessment at the Last Study Visit in Subjects With Neuropathic Pain Due to Multiple Sclerosis.</title>
        <description>Investigators rated the global severity of the subject's underlying primary condition, e.g. their MS or spinal cord injury, since the previous visit using a five point scale of &quot;much worse&quot;, &quot;worse&quot;, &quot;no change&quot;, &quot;better&quot;, &quot;much better&quot;. The number of subjects rated by the investigator as &quot;better&quot; or &quot;much better&quot; at the last study visit is presented.</description>
        <time_frame>Up to 1051 days</time_frame>
        <population>All subjects who entered the study from a parent RCT investigation neuropathic pain due to multiple sclerosis, and who received at least one actuation of study medication were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Global Assessment at the Last Study Visit in Subjects With Neuropathic Pain Due to Multiple Sclerosis.</title>
          <description>Investigators rated the global severity of the subject's underlying primary condition, e.g. their MS or spinal cord injury, since the previous visit using a five point scale of &quot;much worse&quot;, &quot;worse&quot;, &quot;no change&quot;, &quot;better&quot;, &quot;much better&quot;. The number of subjects rated by the investigator as &quot;better&quot; or &quot;much better&quot; at the last study visit is presented.</description>
          <population>All subjects who entered the study from a parent RCT investigation neuropathic pain due to multiple sclerosis, and who received at least one actuation of study medication were included in the efficacy analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="98"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Global Assessment at the Last Study Visit in Subjects With Central Neuropathic Pain.</title>
        <description>Investigators rated the global severity of the subject's underlying primary condition, e.g. their MS or spinal cord injury, since the previous visit using a five point scale of &quot;much worse&quot;, &quot;worse&quot;, &quot;no change&quot;, &quot;better&quot;, &quot;much better&quot;. The number of subjects rated by the investigator as &quot;better&quot; or &quot;much better&quot; at the last study visit is presented.</description>
        <time_frame>Up to 1051 days.</time_frame>
        <population>All subjects who entered the study from a central neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Global Assessment at the Last Study Visit in Subjects With Central Neuropathic Pain.</title>
          <description>Investigators rated the global severity of the subject's underlying primary condition, e.g. their MS or spinal cord injury, since the previous visit using a five point scale of &quot;much worse&quot;, &quot;worse&quot;, &quot;no change&quot;, &quot;better&quot;, &quot;much better&quot;. The number of subjects rated by the investigator as &quot;better&quot; or &quot;much better&quot; at the last study visit is presented.</description>
          <population>All subjects who entered the study from a central neuropathic pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="166"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Global Assessment at the Last Study Visit in Subjects With Pain.</title>
        <description>Investigators rated the global severity of the subject's underlying primary condition, e.g. their MS or spinal cord injury, since the previous visit using a five point scale of &quot;much worse&quot;, &quot;worse&quot;, &quot;no change&quot;, &quot;better&quot;, &quot;much better&quot;. The number of subjects rated by the investigator as &quot;better&quot; or &quot;much better&quot; at the last study visit is presented.</description>
        <time_frame>Up to 1051 days.</time_frame>
        <population>All subjects who entered the study from a pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Global Assessment at the Last Study Visit in Subjects With Pain.</title>
          <description>Investigators rated the global severity of the subject's underlying primary condition, e.g. their MS or spinal cord injury, since the previous visit using a five point scale of &quot;much worse&quot;, &quot;worse&quot;, &quot;no change&quot;, &quot;better&quot;, &quot;much better&quot;. The number of subjects rated by the investigator as &quot;better&quot; or &quot;much better&quot; at the last study visit is presented.</description>
          <population>All subjects who entered the study from a pain parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="312"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="122"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Investigator Global Assessment at the Last Study Visit in Subjects With Multiple Sclerosis.</title>
        <description>Investigators rated the global severity of the subject's underlying primary condition, e.g. their MS or spinal cord injury, since the previous visit using a five point scale of &quot;much worse&quot;, &quot;worse&quot;, &quot;no change&quot;, &quot;better&quot;, &quot;much better&quot;. The number of subjects rated by the investigator as &quot;better&quot; or &quot;much better&quot; at the last study visit is presented.</description>
        <time_frame>Up to 1051 days.</time_frame>
        <population>All subjects who entered the study from a multiple sclerosis parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>GW-1000-02</title>
            <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
          </group>
        </group_list>
        <measure>
          <title>Investigator Global Assessment at the Last Study Visit in Subjects With Multiple Sclerosis.</title>
          <description>Investigators rated the global severity of the subject's underlying primary condition, e.g. their MS or spinal cord injury, since the previous visit using a five point scale of &quot;much worse&quot;, &quot;worse&quot;, &quot;no change&quot;, &quot;better&quot;, &quot;much better&quot;. The number of subjects rated by the investigator as &quot;better&quot; or &quot;much better&quot; at the last study visit is presented.</description>
          <population>All subjects who entered the study from a multiple sclerosis parent RCT and received at least one actuation of study medication were included in the efficacy analysis.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="284"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All adverse events occurring from the extension study onset to the last study visit (up to 1051 days) were collected. All deaths and serious adverse events occurring within 28 days of the final dose of study medication were also collected.</time_frame>
      <desc>All adverse events occurring during the study were reported on the running logs at the back of the study case report form.</desc>
      <group_list>
        <group group_id="E1">
          <title>GW-1000-02</title>
          <description>Each 100 ul actuation contains 27 mg THC and 25 mg CBD. A maximum of 48 actuations (130 mg of THC 120 and mg of CBD) was permitted in any 24 hour period.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 6.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="74" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>VENTRICULAR BIGEMINY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CORNEAL ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>EYELID OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL PAIN NOT OTHERWISE SPECIFIED (NOS)</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>DIARRHOEA NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>VOMITING NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISCOMFORT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>ABDOMINAL DISTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>CONSTIPATION AGGRAVATED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>IRRITABLE BOWEL SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>OESOPHAGITIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL GANGRENE NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>WEAKNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>PAIN EXACERBATED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>DRUG HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>URINARY TRACT INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>SEPSIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>BRONCHOPNEUMONIA NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>KLEBSIELLA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>OESOPHAGEAL CANDIDIASIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>PNEUMONIA NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL SITE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION BACTERIAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>DEVICE FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>FRACTURED PELVIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>INCISIONAL HERNIA NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>MEDICAL DEVICE COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL URINE LEAK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>LIVER FUNCTION TESTS NOS ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>BLOOD IN STOOL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOGLYCAEMIA NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>INGUINAL MASS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>MUSCLE SPASMS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>LUNG CANCER STAGE UNSPECIFIED (EXCL METASTATIC TUMOURS TO LUNG)</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>MALIGNANT MELANOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>MULTIPLE SCLEROSIS RELAPSE</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>MULTIPLE SCLEROSIS AGGRAVATED</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>CONVULSIONS NOS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>DEPRESSED LEVEL OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>DYSARTHRIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>GRAND MAL CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>TREMOR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>DELUSIONAL PERCEPTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>PARANOIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE ON CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>DECUBITUS ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>URTICARIA NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>PREGNANCY OF PARTNER</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>DEEP VENOUS THROMBOSIS NOS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA 6.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="477" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Diarrhoea NOS</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Vomiting NOS</sub_title>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Glossodynia</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Oral Pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Tooth Discolouration</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Weakness</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pain Exacerbated</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Feeling Drunk</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Application Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Influenza Like Illness</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Urinary Tract Infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="111" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection NOS</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Gamma-glutamyltransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Blood Alkaline Phosphatase NOS Increased</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle Spasms</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Pain in Limb</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Headache Not Otherwise Specified (NOS)</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Multiple Sclerosis Aggravated</sub_title>
                <counts group_id="E1" subjects_affected="39" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Multiple Sclerosis Relapse</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Balance Impaired NOS</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Disturbance in Attention</sub_title>
                <counts group_id="E1" subjects_affected="17" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Mouth Ulceration</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Euphoric Mood</sub_title>
                <counts group_id="E1" subjects_affected="22" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Depressed Mood</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="507"/>
              </event>
              <event>
                <sub_title>Rash NOS</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="507"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GW will coordinate the dissemination of data from this study and may solicit input and assistance from the principal investigator. All publications, for example manuscripts, abstracts, oral/slide presentations or book chapters based on this study, must be submitted to GW for corporate review before release.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Mr Richard Potts, Clinical Operations Director</name_or_title>
      <organization>GW Pharma Ltd.</organization>
      <phone>0044 1223 266800</phone>
      <email>rp@gwpharm.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

